Q12 · UPPSC current affairs · 1 October 2026 · PIB · Promotion of Research and Innovation in Pharma MedTech Sector Scheme

← Q11 Q13 →

What are 'Biosimilars' in the context of pharmaceutical research and development?

A Traditional herbal formulations standardized for commercial export
B Medical devices implanted surgically to monitor real-time blood glucose levels
C Biological medical products highly similar to already approved reference biopharmaceuticals with no clinically meaningful differences
D Chemical copycat molecules synthesized entirely from petroleum derivatives without any biological source

Correct answer: (c) Biological medical products highly similar to already approved reference biopharmaceuticals with no clinically meaningful differences

Explanation

Option C correctly defines biosimilars as biological medical products highly similar to already approved reference biopharmaceuticals with no clinical differences. The other options mischaracterize the concept.

Same topic · past papers

UPSC has asked this before

These previous-year questions sit on the same topic. Open one to practise the earlier ask.

  1. 2024 · Q145 · UPPGS

    With reference to the “National Intellectual Property Rights Policy” consider the following statements: 1. It reiterates India's commitment to Doha Development Agenda and the TRIPS agreement. 2. Department of Industrial Policy and Promotion is the nodal agency for regulating Intellectual Property Rights in India. Which of the above statements is/are correct? Select the correct answer from the code given below:

    View answer →

PDF